Liver cirrhosis in the Moscow Region: figures and facts

Cover Page


Cite item

Abstract

The majority of deaths related to complications of liver cirrhosis would have been preventable with timely diagnosis and proper treatment. However, absence of the population-based screening programs for hepatitis, an asymptomatic course of the majority of liver disorders, failures in the registration of etiologically confirmed cases of liver cirrhosis, low population awareness of its risks and of current diagnostic and management opportunities do impede the collection of reliable epidemiological data on the incidence and prevalence of liver disorders including their end-stages, and on the related mortality of the population; as a consequence, all these factors hinder a comprehensive assessment of the medical and social burden of hepatic disorders. Medical registries are the single system for their registration and follow-up. Analysis of data from the Moscow Regional Registry of patients with liver disease has shown that the leading cause of liver cirrhosis is HCV infection (66%), with alcoholic liver cirrhosis ranking second (16.1%). There is a trend towards higher proportions of liver cirrhosis as an outcome of HCV hepatitis among newly referred patients (7.2% in 2012 and 10.6% in 2016). HCV genotype characteristics determine the rates of the disease progression: in those with genotype 3, liver cirrhosis would occur at an earlier age (51.8% of patients aged from 26 to 45) than with genotype 1 (58.7% of patients aged from 46 to 65). In older patients, various comorbidities can contribute to the development of liver cirrhosis. Among patients with HBV infection, 4.9% have liver cirrhosis, and most of patients receive antiviral treatment with nucleoside/nucleotide analogues. The highest percentage of liver cirrhosis has been found in the patients with chronic D hepatitis (46/116, 39.7%). In 10.3% of the patients with chronic D hepatitis, the aggressive course of the disease leads to primary liver cancer. Thus, the necessity of the development of prevention measures and early detection of liver disorders, as well as modernization of the public healthcare system at all stages of medical care should be recognized as the short-term goals, in addition to the search for highly effective etiologic treatment and making it available within the state-financed programs.

About the authors

P. O. Bogomolov

Moscow Regional Research and Clinical Institute (MONIKI)

Email: fake@neicon.ru

Pavel O. Bogomolov – MD, PhD, Head of the Moscow Regional Hepatology Center, Head of Department of Hepatology.

61/2 Shchepkina ul., Moscow, 129110

Russian Federation

M. V. Matsievich

Moscow Regional Research and Clinical Institute (MONIKI)

Author for correspondence.
Email: macievich@gmail.com

Mariya V. Matsievich – MD, PhD, Senior Research Fellow, Department of Hepatology; Gastroenterologist, Hepatology Department, Consultative and Diagnostics Department.

61/2–8 Shchepkina ul., Moscow, 129110, +7 (495) 631 72 90

Russian Federation

A. O. Bueverov

Moscow Regional Research and Clinical Institute (MONIKI); I.M. Sechenov First Moscow State Medical University

Email: fake@neicon.ru

Aleksey O. Bueverov – MD, PhD, Professor, Leading Research Fellow, Department of Hepatology MONIKI; Chair of Medical and Social Expert Assessment and Out-Patient Therapy of the Postgraduate Medical Training Faculty  I.M. Sechenov FMSMU; Leading Research Fellow, Department of Research on Innovative Therapy, Research Center FMSMU.

61/2 Shchepkina ul., Moscow, 129110; 8/2 Trubetskaya ul., Moscow, 119991

Russian Federation

K. Yu. Kokina

Moscow Regional Research and Clinical Institute (MONIKI)

Email: fake@neicon.ru

Kseniya Yu. Kokina – MD, Research Fellow, Department of Hepatology; Gastroenterologist, Hepatology Department, Consultative and Diagnostics Department.

61/2 Shchepkina ul., Moscow, 129110

Russian Federation

N. V. Voronkova

Moscow Regional Research and Clinical Institute (MONIKI)

Email: fake@neicon.ru

Natal'ya V. Voronkova – MD, PhD, Senior Research Fellow, Department of Hepatology; Specialist in Infectious Diseases, Hepatology Department, Consultative and Diagnostics Department.

61/2 Shchepkina ul., Moscow, 129110

Russian Federation

V. D. Beznosenko

Moscow Regional Research and Clinical Institute (MONIKI)

Email: fake@neicon.ru

Valeriy D. Beznosenko – MD, Specialist in Infectious Diseases, Hepatology Department, Consultative and Diagnostics Department.

61/2 Shchepkina ul., Moscow, 129110

Russian Federation

References

  1. Basnayake SK, Easterbrook PJ. Wide variation in estimates of global prevalence and burden of chronic hepatitis B and C infection cited in published literature. J Viral Hepat. 2016;23(7): 545–59. doi: 10.1111/jvh.12519.
  2. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963): 117–71. doi: 10.1016/S0140-6736(14)61682-2.
  3. Rehm J, Taylor B, Mohapatra S, Irving H, Baliunas D, Patra J, Roerecke M. Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis. Drug Alcohol Rev. 2010;29(4): 437–45. doi: 10.1111/j.14653362.2009.00153.x.
  4. Ramond MJ, Poynard T, Rueff B, Mathurin P, Théodore C, Chaput JC, Benhamou JP. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med. 1992;326(8): 507–12. doi: 10.1056/NEJM199202203260802.
  5. Crosse KI, Anania FA. Alcoholic hepatitis. Curr Treat Options Gastroenterol. 2002;5(6): 417–23. doi: 10.1007/s11938-002-0029-7.
  6. Pessione F, Ramond MJ, Peters L, Pham BN, Batel P, Rueff B, Valla DC. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int. 2003;23(1): 45–53. doi: 10.1034/j.16000676.2003.01804.x.
  7. Veldt BJ, Lainé F, Guillygomarc'h A, Lauvin L, Boudjema K, Messner M, Brissot P, Deugnier Y, Moirand R. Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. J Hepatol. 2002;36(1): 93–8. doi: 10.1016/S01688278(01)00228-8.
  8. Кузьмина ОС, Богомолов ПО, Маев ИВ, Мациевич МВ, Буеверов АО, Коблов СВ, Кокина КЮ, Барсукова НА, Уварова ОВ, Павлова ТВ. Хронический гепатит, вызванный вирусом 3-го генотипа: два «лица» одной болезни. Клинические перспективы гастроэнтерологии, гепатологии. 2012;(5): 26–33.
  9. World Health Organization. WHO global health sector strategy on viral hepatitis 2016–2021. Geneva: World Health Organization; 2016. 56 p. [Internet]. Available at: http://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV2016.06-eng.pdf?ua=1 [Accessed 09 January 2017].
  10. Богомолов ПО, Буеверов АО, Мациевич МВ, Петраченкова МЮ, Воронкова НВ, Коблов СВ, Кокина КЮ, Безносенко ВД, Федосова ЕВ. Эпидемиология гепатита C в Московской области: данные регионального регистра и скрининга на антитела к HCV. Альманах клинической медицины. 2016;44(6): 689–96. doi: 10.18786/2072-0505-2016-44-6-689-696.
  11. Natarajan Y, White DL, El-Serag HB, Ramsey D, Richardson P, Kuzniarek J, Shukla R, Tansel A, Kanwal F. Role of non-hepatic medical comorbidity and functional limitations in predicting mortality in patients with HCV. Dig Dis Sci. 2017;62(1): 76–83. doi: 10.1007/s10620-0164303-2.
  12. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383(9930): 1749–61. doi: 10.1016/S0140-6736(14)60121-5.
  13. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1): 217–31. doi: 10.1016/j.jhep.2005.10.013.
  14. Hytiroglou P, Snover DC, Alves V, Balabaud C, Bhathal PS, Bioulac-Sage P, Crawford JM, Dhillon AP, Ferrell L, Guido M, Nakanuma Y, Paradis V, Quaglia A, Theise ND, Thung SN, Tsui WM, van Leeuwen DJ. Beyond "cirrhosis": a proposal from the International Liver Pathology Study Group. Am J Clin Pathol. 2012;137(1): 5–9. doi: 10.1309/AJCP2T2OHTAPBTMP.

Supplementary files

There are no supplementary files to display.


Copyright (c) 2018 Bogomolov P.O., Matsievich M.V., Bueverov A.O., Kokina K.Y., Voronkova N.V., Beznosenko V.D.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies